Transcriptome-wide Mendelian randomization study prioritising novel tissue-dependent genes for glioma susceptibility

Abstract

Genome-wide association studies (GWAS) have discovered 27 loci associated with glioma risk. Whether these loci are causally implicated in glioma risk, and how risk differs across tissues, has yet to be systematically explored. We integrated multi-tissue expression quantitative trait loci (eQTLs) and glioma GWAS data using a combined Mendelian randomisation (MR) and colocalisation approach. We investigated how genetically predicted gene expression affects risk across tissue type (brain, estimated effective n = 1194 and whole blood, n = 31,684) and glioma subtype (all glioma (7400 cases, 8257 controls) glioblastoma (GBM, 3112 cases) and non-GBM gliomas (2411 cases)). We also leveraged tissue-specific eQTLs collected from 13 brain tissues (n = 114 to 209). The MR and colocalisation results suggested that genetically predicted increased gene expression of 12 genes were associated with glioma, GBM and/or non-GBM risk, three of which are novel glioma susceptibility genes (RETREG2/FAM134A, FAM178B and MVB12B/FAM125B). The effect of gene expression appears to be relatively consistent across glioma subtype diagnoses. Examining how risk differed across 13 brain tissues highlighted five candidate tissues (cerebellum, cortex, and the putamen, nucleus accumbens and caudate basal ganglia) and four previously implicated genes (JAK1, STMN3, PICK1 and EGFR). These analyses identified robust causal evidence for 12 genes and glioma risk, three of which are novel. The correlation of MR estimates in brain and blood are consistently low which suggested that tissue specificity needs to be carefully considered for glioma. Our results have implicated genes yet to be associated with glioma susceptibility and provided insight into putatively causal pathways for glioma risk.

An organoid library of salivary gland tumors reveals subtype-specific characteristics and biomarkers

“…7 D). It is a protein-coding gene with an unrecorded function, and a recent transcriptome-wide study identified FAM178B as a novel susceptibility gene for glioma [ 49 ]. However, the role of FAM178B in ACC is unknown, and it is interesting to further investigate its potential as a clinical diagnostic marker for ACC.…”

The Scaffold Protein PICK1 as a Target in Chronic Pain

“…Additionally, the siRNA-mediated knock down of PICK1 in MDA-MB-231 cells decreased cell proliferation and colony formation in vitro and inhibited tumorigenicity in nude mice [105], presenting PICK1 as a putative target in cancer. More recently, a transcriptome-wide Mendelian randomization study implicated an increased PICK1 expression as the most prominent risk factor for glioma susceptibility [110]. On the other hand, the effect of the microRNA, miR-615-3p, in promoting the epithelial-mesenchymal transition (EMT) in breast cancer cells was shown to rely on targeting the 3 -untranslated regions of PICK1 causing the inhibition of PICK1 translation and an increase in the downstream signaling of transforming growth factor β (TGFβ) [108].…”

Safety and efficacy of a evidence-based nursing practice on early mobilization after surgery for glioma: a historical control study

“…These two coincided and crossed in uence each other and followed by complications after the surgery operation. As a result, the prognosis of patients with glioma varies considerably 5 . Henrik Kehlet rst described the concept of Enhance Recovery After Surgery (ERAS) in colorectal surgery in 1997 6 .…”